Статья
ВЫБОР САХАРОСНИЖАЮЩИХ ПРЕПАРАТОВ У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2-ГО ТИПА ОЧЕНЬ ВЫСОКОГО СЕРДЕЧНО-СОСУДИСТОГО РИСКА (ЧАСТЬ 1)
В первой части обзора представлены особенности выбора традиционных сахароснижающих препаратов у больных сахарным диабетом 2-го типа в сочетании с сердечно-сосудистыми заболеваниями атеросклеротического генеза. Особое внимание уделено больным с хронической сердечной недостаточностью. В тактике ведения пациентов с сахарным диабетом 2-го типа очень высокого сердечно-сосудистого риска отражено большое значение определения индивидуализированного выбора целевого уровня гликированного гемоглобина, который у данной категории больных более высокий. Проведен анализ безопасности выбора сахароснижающих препаратов из групп бигуанидов, меглитинидов, ингибиторов альфа-глюкозидазы, инсулина и сульфанилмочевины. Оценка рандомизированных клинических исследований, метаанализов опубликованных исследований по безопасности сахароснижающих препаратов в отношении сердечнососудистой системы показала, что препаратами первой линии в инициации лечения больных очень высокого сердечно-сосудистого риска, как в монотерапии, так и в комбинации, в зависимости от исходного уровня гликированного гемоглобина, являются бигуаниды (метформин) — лекарственные средства, улучшающие прогноз, обеспечивающие снижение риска развития сердечно-сосудистых событий. Применение ряда препаратов инсулина ухудшает прогноз больных при наличии сердечно-сосудистых заболеваний. Безопасность в отношении кардиоваскулярных исходов доказана для инсулина гларгина. Препараты сульфонилмочевины (за исключением гликлазида), меглитиниды, ингибиторы альфа-глюкозидазы не рекомендуются для лечения больных сахарным диабетом 2-го типа очень высокого сердечно-сосудистого риска из-за наличия доказательств негативного влияния на прогноз, либо из-за отсутствия достаточных аргументов в пользу безопасности в отношении сердечно-сосудистой системы, либо результаты исследований противоречивы. Особенности выбора и назначения «новых» групп сахароснижающих препаратов будут представлены во второй части статьи.
1. Дедов И. И., Шестакова М. В., Галстян Г. Р., Григорян О. Р., Есаян М. Р., Калашников В. Ю. и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И. И. Дедова, М. В. Шестаковой. Сахарный диабет. 2015;18(1S):1–112..
2. Gruneir A, Markle-Reid M, Fisher K, Reimer H, Ma X, Ploeg J et al. Comorbidity burden and health services use in community-living older adults with diabetes mellitus: a retrospective cohort study. Can J Diabetes. 2016;40(1):35–42. doi: 10.1016/j.jcjd.2015.09.002
3. Gao N, Yuan Z, Tang X, Zhou X, Zhao M, Liu L et al. Prevalence of CHD-related metabolic comorbidity of diabetes mellitus in Northern Chinese adults: the REACTION study. J Diabetes Complications. 2016;30(2):199–205. doi: 10.1016/j.jdiacomp.2015.11.018
4. Bartnik M, Rydén L, Ferrari R, Malmberg K, Pyörälä K, Simoons M et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J. 2004;25 (21):1880–90. doi: 10.1016/j.ehj.2004.07.027
5. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts): Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315–81. doi: 10.1093/eurheartj/ehw106
6. Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O et al. ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for themanagement of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3–46. PMID:21882396.
7. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. V пересмотр. Атеросклероз и дислипидемии. 2012;4:4–53..
8. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2889–934. doi: 10.1016/j.jacc.2013.11.002
9. Cavender MA, Steg PG, Smith SC Jr, Eagle K, Ohman EM, Goto S et al. Impact of diabetes mellitus on hospitalization for heart failure, cardiovascular events, and death: outcomes at 4 years from the reduction of atherothrombosis for continued health (REACH) registry. Circulation. 2015;132(10):923–31. doi: 10.1161/CIRCULATIONAHA.114.014796
10. McDonald CG, Majumdar SR, Mahon JL, Johnson JA. The effectiveness of beta-blockers after myocardial infarction in patients with type 2 diabetes. Dia Care. 2005;28(9):2113–17. PMID:16123475
11. Andersson J, Wennberg P, Lundblad D, Escher SA, Jansson JH. Diabetes mellitus, high BMI and low education level predict sudden cardiac death within 24 hours of incident m y o c a r d i a l i n f a r c t i o n . E u r J P r e v C a r d i o l . 2 0 1 6 . p i i : 2047487316659574. doi:10.1177/2047487316659574.
12. Li W, Li M, Gao C, Wang X, Qi D, Liu J, Jin Q. Impact of type 2 diabetes mellitus on recurrent myocardial infarction in China. Diab Vasc Dis Res. 2016. pii:1479164116653606. doi: 10.1177/1479164116653606
13. Jing J, Pan Y, Zhao X, Zheng H, Jia Q, Li H. Prognosis of ischemic stroke with newly diagnosed diabetes mellitus according to hemoglobin A1c сriteria in Chinese зopulation. Stroke. 2016;47 (8):2038–44. doi: 10.1161/STROKEAHA.116.013606
14. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. Lancet. 2010;375(9733):2215– 22. doi: 10.1016/S0140–6736(10)60484–9.
15. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD — summary. Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Diab Vasc Dis Res. 2014;11(3):133–73. doi: 10.1177/1479164114525548
16. Transcript for FDA’s Media Briefing: Guidance Document — diabetes mellitus, evaluating cardiovascular risk and new anti-diabetic therapies to treat type II вiabetes. Moderator: Karen Riley. December 17, 2008. Available from: http://www.fda.gov/downloads/NewsEvents/Newsroom/MediaTranscripts/ucm121231.pdf
17. European Medicines Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf.Accessed 12 Jan 2016.
18. Forst T, Hanefeld M, Jacob S, Moeser G, Schwenk G, Pfützner A, Haupt A. Association of sulphonylurea treatment with all-cause and cardiovascular mortality: a systematic review and meta-analysis of observational studies. Diab Vasc Dis Res. 2013;10 (4):302–14. doi: 10.1177/1479164112465442
19. Hung YC, Lin CC, Wang TY, Chang MP, Sung FC, Chen CC. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes m e l l i t u s . D i a b e t e s M e t a b R e s R e v. 2 0 1 3 ; 2 9 ( 8 ) : 6 7 3 – 9 . doi: 10.1002/dmrr.2444
20. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab. 2012;14(9):803–9. doi: 10.1111/j.1463–1326.2012.01604.x
21. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J. 2011;32 (15):1900–8. doi: 10.1093/eurheartj/ehr077
22. Jørgensen CH, Gislason GH, Andersson C, Ahlehoff O, Charlot M, Schramm TK et al. Effects of oral glucose-lowering drugs on long-term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention a retrospective nationwide cohort study. Cardiovasc Diabetol. 2010;9:54. doi: 10.1186/1475–2840–9–54
23. Landman GW, de Bock GH, van Hateren KJ, van Dijk PR, Groenier KH, Gans RO, et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and metaanalysis of randomized trials. PLoS One. 2014;9(2):e82880. doi: 10.1371/journal.pone.0082880
24. Patel A, MacMahon S, Chalmers J, Woodward M, Billot L, Harrap S et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370(9590):829–40. doi: 10.1016/S0140–6736(07)61303–8
25. Huang Y, Abdelmoneim AS, Light P, Qiu W, Simpson SH. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complications. 2015;29(2):196–202. doi: 10.1016/j.jdiacomp.2014.11.012
26. Li Y, Hu Y, Ley SH, Rajpathak S, Hu FB. Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women. Diabetes Care. 2014. pii: DC_141306. doi: 10.2337/dc14–1306
27. Seong JM, Choi NK, Shin JY, Chang Y, Kim YJ, Lee J et al. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study. PLoS One. 2015;10(5): e0124287. doi: 10.1371/journal.pone.0124287
28. Eriksson JW, Bodegard J, Nathanson D, Thuresson M, Nyström T, Norhammar A. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality. Diabetes Res Clin Pract. 2016;117:39–47. doi: 10.1016/j.diabres.2016.04.055
29. McAlister FA, Eurich DT, Majumdar SR, Johnson JA. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail. 2008;10(7):703–8. doi:10.1016/j.ejheart.2008.05.013
30. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies. Metabolism. 2013;62(7):922–34. doi: 10.1016/j.metabol.2013.01.014
31. Викулова О. К., Шестакова М. В. Терапия глибенкламидом: за или против? Сахарный диабет. 2011;3:92–6..
32. Kottenberg E, Thielmann M, Kleinbongard P, Frey UH, Heine T, Jakob H et al. Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation. Acta Anaesthesiol Scand. 2014;58(4):453–62. doi: 10.1111/aas.12278
33. . URL: http://www.vidal.ru/drugs/molecule/468
34. ORIGIN Trial Investigators. Mellbin LG, Ryden L, Riddle MC, Probstfield J, Rosenstock J, Díaz R et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. Eur Heart J. 2013;34(40):3137–44. doi: 10.1093/eurheartj/eht332
35. Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. Br Med J.м2010;340: b4909. doi: 10.1136/bmj.b4909
36. Cha SA, Yun JS, Lim TS, Hwang S, Yim EJ, Song KH et al. Severe hypoglycemia and cardiovascular or all-cause mortality in patients with type 2 diabetes. Diabetes Metab J. 2016;40(3):202–10. doi: 10.4093/dmj.2016.40.3.202
37. Jin Q, Lou Y, Chen H, Li T, Bao X, Liu Q, He X. Lower free testosterone level is correlated with left ventricular diastolic dysfunction in asymptomatic middle-aged men with type 2 diabetes mellitus. Int J Clin Pract. 2014;68(12):1454–61. doi: 10.1111/ijcp.12481
38. Stahn A, Pistrosch F, Ganz X, Teige M, Koehler C, Bornstein S et al. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias. Diabetes Care. 2014;37(2):516–20. doi: 10.2337/dc13–0600
39. Bedenis R, Price AH, Robertson CM, Morling JR, Frier BM, Strachan MW et al. Association between severe hypoglycemia, adverse macrovascular events, and inflammation in the Edinburgh type 2 diabetes study. Diabetes Care. 2014;37(12):3301–8. doi: 10.2337/dc14–0908
40. Adler GK, Bonyhay I, Failing H, Waring E, Dotson S, Freeman R. Antecedent hypoglycemia impairs autonomic cardiovascular function: implications for rigorous glycemic control. Diabetes. 2009;58(2):360–6. doi: 10.2337/db08–1153
41. van Dalem J, Brouwers MC, Stehouwer CD, Krings A, Leufkens HG, Driessen JH et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. Br Med J. 2016;354: i3625. doi: 10.1136/bmj.i3625
42. Mearns ES, Saulsberry WJ, White CM, Kohn CG, Lemieux S, SihaboutAet al. Efficacy and safety of antihyperglycaemic drug regimens added to metformin and sulphonylurea therapy in type 2 diabetes: a network meta-analysis. Diabet Med. 2015;32 (12):1530–40. doi: 10.1111/dme.12837
43. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):854–65. PMID:9742977
44. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89. doi: 10.1056/NEJMoa0806470
45. Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care. 2013;36(5):1304–11. doi: 10.2337/dc12–0719
46. 6 . A g u i l a r D , C h a n W, B o z k u r t B , R a m a s u b b u K , Deswal A. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail. 2011;4(1):53–8. doi: 10.1161/CIRCHEARTFAILURE.110.952556
47. Eurich DT, Weir DL, Majumdar SR, Tsuyuki RT, Johnson JA, Tjosvold L et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail. 2013;6(3):395–402. doi: 10.1161/CIRCHEARTFAILURE.112.000162
48. Executive summary: Standards of medical care in diabetes 2014. Diabetes Care. 2014;37 Suppl 1: S5–13. doi: 10.2337/dc14-S005
49. Fácila L, Fabregat-Andrés Ó, Bertomeu V, Navarro JP, Miñana G, García-Blas S et al. Metformin and risk of long-term mortality following and admission for acute heart failure. J Cardiovasc Med (Hagerstown). 2016. doi: 10.2459/JCM.0000000000000420
50. Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011;60(6):1770–8. doi: 10.2337/db10–0351
51. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M et al. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3signalling pathway. Cardiovasc Res. 2010;87:504–13. doi: 10.1093/cvr/cvq066
52. Yin M, van der Horst IC, van Melle JP, Qian C, van Gilst WH, Silljé HH et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011;301(2): H459–68. doi: 10.1152/ajpheart.00054.2011
53. Cittadini A, Napoli R, Monti MG, Rea D, Longobardi S, Netti PA et al. Metformin prevents the development of chronic heart failure in the SHHF rat model. Diabetes. 2012;61(4):944–53. doi: 10.2337/db11–1132
54. U RL: http://ww w.vidal.ru/drugs/glucophage_long 24143
55. Ou HT, Chang KC, Li CY, Wu JS. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nationwide longitudinal study. Cardiovasc Diabetol. 2016;15:41. doi: 10.1186/s12933–016–0350–4
56. Cioffi G, Faggiano P, Lucci D, Maggioni AP, Manicardi V, Travaglini A et al. Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: The DYDA study. Diabetes Res Clin Pract. 2013;101(2):236–42. doi: 10.1016/j.diabres.2013.05.010
57. Germino FW. Noninsulin treatment of type 2 diabetesиmellitus in geriatric patients: a review. Clin Ther. 2011;33(12):1868–82. doi: 10.1016/j.clinthera.2011.10.020
58. Huang Y, Abdelmoneim AS, Light P, Qiu W, Simpson SH. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complications. 2015;29(2):196–202. doi: 10.1016/j.jdiacomp.2014.11.012
59. Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA et al. Effect of nateglinide on the incidence o f d i a b e t e s a n d c a r d i o v a s c u l a r e v e n t s . N E n g l J M e d . 2010;362(16):1463–76. doi: 10.1056/NEJMoa1001122
60. Kataoka Y, Yasuda S, Miyamoto Y, Sase K, Kosuge M, Kimura K et al. Effects of voglibose and nateglinide on glycemic status and coronary atherosclerosis in early-stage diabetic patients. Circ J. 2012;76(3):712–20. PMID: 22240597
61. Sawada T, Shiotani H, Terashita D, Nagasawa Y, Kim SS, Koide M et al. Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease. Circ J. 2014;78(1):248–55. PMID: 24225338
62. Huang Y, Abdelmoneim AS, Light P, Qiu W, Simpson SH. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. J Diabetes Complications. 2015;29(2):196–202. doi: 10.1016/j.jdiacomp.2014.11.012
63. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290(4):486–94. doi: 10.1001/jama.290.4.486
64. Yun P, Du AM, Chen XJ, Liu JC, Xiao H. Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance. J Diabetes Res. 2016;2016:1602083. doi: 10.1155/2016/1602083
65. Koyasu M, Ishii H, Watarai M, Takemoto K, Inden Y, Takeshita K et al. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease. Clin Ther. 2010;32(9):1610–7. doi: 10.1016/j.clinthera.2010.07.015
66. Chen JM, Chang CW, Lin YC, Horng JT, Sheu WH. Acarbose treatment and the risk of cardiovascular disease in type 2 diabetic patients: a nationwide seven-year follow-up study. J Diabetes Res. 2014;2014:812628. doi: 10.1155/2014/812628
67. Chang CH, Chang YC, Lin JW, Chen ST, Chuang LM, Lai MS. Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study. J Clin Endocrinol Metab. 2015;100 (3):1121–9. doi: 10.1210/jc.2014–2443
68. Wang H, Ni Y, Yang S, Li H, Li X, Feng B. The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus. Curr Ther Res Clin Exp. 2013;75:88–92. doi: 10.1016/j.curtheres.2013.10.002
69. Gentilcore D, Vanis L, Wishart JM, Rayner CK, Horowitz M, Jones KL. The alpha (α)-glucosidase inhibitor, acarbose, attenuates the blood pressure and splanchnic blood flow responses to intraduodenal sucrose in older adults. J Gerontol A Biol Sci Med Sci. 2011;66(8):917–24. doi:10.1093/gerona/glr086
70. Digoxin: serious drug interactions. Prescrire Int. 2010;19 (106):68–70. PMID:20568489
71. URL: http://www.vidal.ru/drugs/molecule/2
72. Chang YC, Chuang LM, Lin JW, Chen ST, Lai MS, Chang CH. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study. Diabet Med. 2015;32 (11):1460–9. doi: 10.1111/dme.12800
73. Ke CC, Lai HC, Lin CH, Hung CJ, Chen DY, Sheu WH et al. Increased risk of Herpes Zoster in diabetic patients comorbid with coronary artery disease and microvascular disorders: a populationbased study in Taiwan. PLoS One. 2016;11(1): e0146750. doi: 10.1371/journal.pone.0146750
74. Moghissi ES, Korytkowski MT, DiNardo M, Einhorn D, Hellman R, Hirsch IB et al. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32 (6):1119–31. doi: 10.2337/dc09–9029
75. Standards of medical care in diabetes 2014. American Diabetes Association. Diabetes Care. 2014;37 Suppl 1: S14–80. doi: 10.2337/dc14-S014
76. Chamberlain JJ, Rhinehart AS, Shaefer CF, Neuman A. Diagnosis and Management of Diabetes: Synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. 2016;164(8):542–52. doi: 0.7326/M15–3016
77. URL: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetab olicDrugsAdvisoryCommittee/UCM330923.pdf last accessed 27.05.2013
78. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, C o h e n R M , C u s h m a n W C e t a l . O u t c o m e s o f c o m b i n e d cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721–8. doi: 10.2337/dc13–2334
79. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. doi: 10.1056/NEJMoa0808431
80. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–53. PMID: 9742976
81. Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319–28. doi: 10.1056/NEJMoa1203858
82. ORIGIN Trial Investigators. Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care. 2016;39(5):709–16. doi: 10.2337/dc15–1676
83. Riddle MC, Yki-Järvinen H, Bolli GB, Ziemen M, Muehlen-Bartmer I, Cissokho S et al. One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month extension. Diabetes Obes Metab. 2015;17 (9):835–42. doi: 10.1111/dom.12472
84. URL : ht tps: //clinicaltrialsgov/ct2/show/NCT01959529?term=DEVOTE&rank=1
85. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372(23):2197–206. doi: 10.1056/NEJMoa1414266
86. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373 (9677):1765–72. doi: 10.1016/S0140–6736 (09)60697–8
87. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Br Med J. 2011;343: d4169. doi: 10.1136/bmj.d4169
88. Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2013;(11): CD008143. doi: 10.1002/14651858.CD008143.pub3
89. Li J, Tong Y, Zhang Y, Tang L, Lv Q, Zhang F et al. Effects on all-cause mortality and cardiovascular outcomes in patients with type 2 diabetes by comparing insulin with oral hypoglycemic agent therapy: a meta-analysis of randomized controlled trials. Clin Ther. 2016;38(2):372–386.e6. doi: 10.1016/j.clinthera.2015.12.006
90. Currie CJ, Poole CD, Evans M, Peters JR, Morgan CL. Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes. J Clin Endocrinol Metab. 2013;98(2):668–77. doi: 10.1210/jc.2012–3042
91. Holden SE, Jenkins-Jones S, Morgan CL, Schernthaner G, Currie CJ. Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer. Diabetes Obes Metab. 2015;17 (4):350–62. doi: 10.1111/dom.12412
92. Anyanwagu U, Mamza J, Mehta R, Donnelly R, Idris I. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes. Heart. 2016;102(19):1581–1587. pii: heartjnl-2015–309164. doi: 10.1136/heartjnl2015–309164.
93. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. J Am Med Assoc. 2014;311(22):2288–96. doi: 10.1001/jama.2014.4312
94. Nijjar AP, Wang H, Quan H, Khan NA. Antihyperglycemic therapy and cardiovascular outcomes after acute myocardial infarction in elderly patients with diabetes. Can J Diabetes. 2014;38 (6):396–400. doi: 10.1016/j.jcjd.2014.03.004
95. Wit MA, de Mulder M, Jansen EK, Umans VA. Diabetes mellitus and its impact on long-term outcomes after coronary artery bypass graft surgery. Acta Diabetol. 2013;50(2):123–8. doi: 10.1007/s00592–010–0223–3
96. Bundhun PK, Li N, Chen MH. Adverse cardiovascular outcomes between insulin-treated and non-insulin treated diabetic patients after percutaneous coronary intervention: a systematic review and meta-analysis. Cardiovasc Diabetol. 2015;14:135. doi: 10.1186/s12933–015–0300–6
97. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent STSegment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267–315. doi: 10.1093/eurheartj/ehv320
98. Steg PG, James SK, Atar D, Badano LP, BlomstromLundqvist C, Borger MA et al. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569–619. doi: 10.1093/eurheartj/ehs215
99. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359–67. doi: 10.1056/NEJMoa011300
100. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360(13):1283–97. doi: 10.1056/NEJMoa0810625
101. Núñez J, Bonanad C, Navarro JP, Bondanza L, Artero A, Ventura S et al. Differential effect of glycosylated hemoglobin value and antidiabetic treatment on the risk of 30-day readmission following a hospitalization for acute heart failure. Rev Esp Cardiol (Engl Ed). 2015;68(10):852–60. doi: 10.1016/j.rec.2014.10.019
102. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766–77. doi: 10.1007/s00125–009–1440–6
103. Defronzo RA. Is insulin resistance atherogenic? Possible mechanisms. Atheroscler Suppl. 2006;7(4):11–5. doi: 10.1016/j.atherosclerosissup.2006.05.002
104. Nkondi Mbadi AN, Longo-Mbenza B, Mvitu Muaka M, Mbungu FS, Lemogoum D. Relationship between pulse pressure, visual impairement and severity of diabetic retinopathy in subSaharan Africa. Mali Med. 2009;24(3):17–21. PMID:20093220
105. Hashimoto J, Ito S. Central pulse pressure and aortic stiffness determine renal hemodynamics: pathophysiological implication for microalbuminuria in hypertension. Hypertension. 2011;58(5):839–46. doi: 10.1161/HYPERTENSIONAHA.111.177469
106. Ramakrishna V, Jailkhani R. Oxidative stress in noninsulin-dependent diabetes mellitus (NIDDM) patients. Acta Diabetologica. 2008;45(1):41–6. doi: 10.1007/s00592–007–0018–3
107. Jankovic D, Winhofer Y, Promintzer-Schifferl M, Wohlschläger-Krenn E, Anderwald CH, Wolf P et al. Effects of insulin therapy on myocardial lipid content and cardiac geometry in patients with type-2 diabetes mellitus. PLoS One. 2012;7(12): e50077. doi: 10.1371/journal.pone.0050077